source
- FDA reinspects Novo Nordisk's Indiana plant, finds mammalian hair and roof leaks compromising drug sterilityNovo Nordisk's manufacturing facility in Indiana, acquired from Catalent, has undergone a second FDA reinspection after earlier concerns. The April inspection revealed mammalian hair in finished d…
- Hikma invests $267 million in Ohio as Cingulate receives CRL for ADHD candidateHikma Pharmaceuticals, a generic drugmaker, announced a $267 million investment to expand its manufacturing footprint in Ohio. The plan includes $216 million to upgrade its existing Columbus plant…